Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

CG Oncology (CGON) Net Margin (2023 - 2025)

CG Oncology's Net Margin history spans 3 years, with the latest figure at 1776.74% for Q4 2025.

  • For Q4 2025, Net Margin rose 519650.0% year-over-year to 1776.74%; the TTM value through Dec 2025 reached 3981.26%, up 374806.0%, while the annual FY2025 figure was 3985.02%, 374447.0% up from the prior year.
  • Net Margin reached 1776.74% in Q4 2025 per CGON's latest filing, up from 2623.53% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 1776.74% in Q4 2025 to a low of 2249000.0% in Q4 2023.
  • Average Net Margin over 3 years is 259531.23%, with a median of 12001.04% recorded in 2024.
  • Peak YoY movement for Net Margin: soared 224202675bps in 2024, then plummeted -6306271bps in 2025.
  • A 3-year view of Net Margin shows it stood at 2249000.0% in 2023, then skyrocketed by 100bps to 6973.25% in 2024, then soared by 75bps to 1776.74% in 2025.
  • Per Business Quant, the three most recent readings for CGON's Net Margin are 1776.74% (Q4 2025), 2623.53% (Q3 2025), and 66263.46% (Q1 2025).